Novartis AG Total Liabilities

Latest as of March 2026: MX$79.61 Billion MXN ≈ $4.58 Billion USD

Novartis AG total liabilities. Based on the latest financial reports, Novartis AG (NVSN) has total liabilities worth MX$79.61 Billion MXN (≈ $4.58 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Novartis AG to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Novartis AG (2014–2025)

Total liabilities of Novartis AG from 2014 to 2025. This chart illustrates how Novartis AG's total liabilities have evolved over time, based on quarterly financial data. Explore NVSN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Novartis AG Competitors by Total Liabilities

The table below lists competitors of Novartis AG ranked by their total liabilities.

Company Country Total Liabilities
The Home Depot Inc
NYSE:HD
USA $94.16 Billion
PetroChina Co Ltd Class A
SHG:601857
China CN¥1.10 Trillion
GE Aerospace
NYSE:GE
USA $110.15 Billion
Palantir Technologies Inc. Class A Common Stock
NYSE:PLTR
USA $1.22 Billion
HSBC Holdings plc
MX:HBCN
Mexico MX$3.04 Trillion
Intel Corporation
NASDAQ:INTC
USA $99.30 Billion
Merck & Company Inc
NYSE:MRK
USA $87.82 Billion
Cisco Systems Inc
NASDAQ:CSCO
USA $75.65 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Novartis AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Novartis AG assets under control.

Liquidity & Leverage Metrics

Novartis AG Total Liabilities Ratios Explained

Novartis AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.85 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.67 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novartis AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novartis AG (2014–2025)

The table below shows the annual total liabilities of Novartis AG from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 MX$64.40 Billion
≈ $3.71 Billion
+10.81%
2024-12-31 MX$58.12 Billion
≈ $3.34 Billion
+9.26%
2023-12-31 MX$53.20 Billion
≈ $3.06 Billion
-8.33%
2022-12-31 MX$58.03 Billion
≈ $3.34 Billion
-9.29%
2021-12-31 MX$63.97 Billion
≈ $3.68 Billion
-15.15%
2020-12-31 MX$75.39 Billion
≈ $4.34 Billion
+20.02%
2019-12-31 MX$62.82 Billion
≈ $3.62 Billion
-6.06%
2018-12-31 MX$66.87 Billion
≈ $3.85 Billion
+13.63%
2017-12-31 MX$58.85 Billion
≈ $3.39 Billion
+6.55%
2016-12-31 MX$55.23 Billion
≈ $3.18 Billion
+1.47%
2015-12-31 MX$54.43 Billion
≈ $3.13 Billion
-0.20%
2014-12-31 MX$54.54 Billion
≈ $3.14 Billion
--

About Novartis AG

MX:NVSN Mexico Drug Manufacturers - General
Market Cap
$319.66 Billion
MX$5.55 Trillion MXN
Market Cap Rank
#51 Global
#1 in Mexico
Share Price
MX$2911.00
Change (1 day)
+4.06%
52-Week Range
MX$2298.00 - MX$2922.00
All Time High
MX$2922.00
About

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more